Digital Pathology-based Artificial Intelligence Biomarker Validation in Metastatic Prostate Cancer.

Journal: European urology oncology
Published Date:

Abstract

BACKGROUND AND OBJECTIVE: Owing to the expansion of treatment options for metastatic hormone-sensitive prostate cancer (mHSPC) and an appreciation of clinical subgroups with differential prognosis and treatment responses, prognostic and predictive biomarkers are needed to personalize care in this setting. Our aim was to evaluate a multimodal artificial intelligence (MMAI) biomarker for prognostic ability in mHSPC.

Authors

  • Mark C Markowski
    John Hopkins University, Baltimore, MD, USA. Electronic address: mmarko12@jhmi.edu.
  • Yi Ren
    Institute for Advanced Study, Shenzhen University, Shenzhen, 518060, P. R. China.
  • Meghan Tierney
    Artera Inc., Los Altos, California.
  • Trevor J Royce
    Artera Inc., Los Altos, CA, USA.
  • Rikiya Yamashita
    Artera, Inc., Los Altos, CA.
  • Danielle Croucher
    Artera Inc, Los Altos, CA, USA.
  • Huei-Chung Huang
    Artera, Inc., Los Altos, CA.
  • Tamara Todorovic
    Artera Inc., Los Altos, CA, USA.
  • Emmalyn Chen
    Artera, Inc., Los Altos, CA.
  • Timothy N Showalter
    Artera Inc., Los Altos, CA, USA; University of Virginia, Charlottesville, VA, USA.
  • Michael A Carducci
    Lauren C. Harshman and Christopher J. Sweeney, Dana-Farber Cancer Institute, Harvard Medical School; Yu-Hui Chen, Dana-Farber Cancer Institute, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group, Boston, MA; Glenn Liu and David Jarrard, University of Wisconsin School of Medicine and Public Health and Carbone Cancer Center, Madison, WI; Michael A. Carducci, Noah Hahn, and Mario Eisenberger, Johns Hopkins University, Baltimore, MD; Robert Dreicer, University of Virginia Cancer Center, Charlottesville, VA; Jorge A. Garcia, Cleveland Clinic Taussig Cancer Institute; Matthew Cooney, University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, OH; Maha Hussain, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago; Daniel Shevrin, NorthShore University Health System, Evanston, IL; Manish Kohli, Mayo Clinic, Rochester, MN; Elizabeth R. Plimack, Fox Chase Cancer Center, Temple Health, Philadelphia, PA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Joel Picus, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO; and Robert Dipaola, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.
  • Yu-Hui Chen
    Lauren C. Harshman and Christopher J. Sweeney, Dana-Farber Cancer Institute, Harvard Medical School; Yu-Hui Chen, Dana-Farber Cancer Institute, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group, Boston, MA; Glenn Liu and David Jarrard, University of Wisconsin School of Medicine and Public Health and Carbone Cancer Center, Madison, WI; Michael A. Carducci, Noah Hahn, and Mario Eisenberger, Johns Hopkins University, Baltimore, MD; Robert Dreicer, University of Virginia Cancer Center, Charlottesville, VA; Jorge A. Garcia, Cleveland Clinic Taussig Cancer Institute; Matthew Cooney, University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, OH; Maha Hussain, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago; Daniel Shevrin, NorthShore University Health System, Evanston, IL; Manish Kohli, Mayo Clinic, Rochester, MN; Elizabeth R. Plimack, Fox Chase Cancer Center, Temple Health, Philadelphia, PA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Joel Picus, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO; and Robert Dipaola, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.
  • Glenn Liu
    Lauren C. Harshman and Christopher J. Sweeney, Dana-Farber Cancer Institute, Harvard Medical School; Yu-Hui Chen, Dana-Farber Cancer Institute, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group, Boston, MA; Glenn Liu and David Jarrard, University of Wisconsin School of Medicine and Public Health and Carbone Cancer Center, Madison, WI; Michael A. Carducci, Noah Hahn, and Mario Eisenberger, Johns Hopkins University, Baltimore, MD; Robert Dreicer, University of Virginia Cancer Center, Charlottesville, VA; Jorge A. Garcia, Cleveland Clinic Taussig Cancer Institute; Matthew Cooney, University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, OH; Maha Hussain, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago; Daniel Shevrin, NorthShore University Health System, Evanston, IL; Manish Kohli, Mayo Clinic, Rochester, MN; Elizabeth R. Plimack, Fox Chase Cancer Center, Temple Health, Philadelphia, PA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Joel Picus, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO; and Robert Dipaola, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.
  • Charles T A Parker
    UCL Cancer Institute, University College London, London, UK.
  • Andre Esteva
    Artera, Inc., Los Altos, CA.
  • Felix Y Feng
    Department of Radiation Oncology, University of California, San Francisco, San Francisco.
  • Gerhardt Attard
    Cancer Institute, University College London, London, United Kingdom.
  • Christopher J Sweeney
    Lauren C. Harshman and Christopher J. Sweeney, Dana-Farber Cancer Institute, Harvard Medical School; Yu-Hui Chen, Dana-Farber Cancer Institute, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group, Boston, MA; Glenn Liu and David Jarrard, University of Wisconsin School of Medicine and Public Health and Carbone Cancer Center, Madison, WI; Michael A. Carducci, Noah Hahn, and Mario Eisenberger, Johns Hopkins University, Baltimore, MD; Robert Dreicer, University of Virginia Cancer Center, Charlottesville, VA; Jorge A. Garcia, Cleveland Clinic Taussig Cancer Institute; Matthew Cooney, University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, OH; Maha Hussain, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago; Daniel Shevrin, NorthShore University Health System, Evanston, IL; Manish Kohli, Mayo Clinic, Rochester, MN; Elizabeth R. Plimack, Fox Chase Cancer Center, Temple Health, Philadelphia, PA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Joel Picus, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO; and Robert Dipaola, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.